Lipocine (STU:2VT0) Cyclically Adjusted FCF per Share: €-3.52 (As of Mar. 2026)


STU:2VT0 Lipocine Inc STU:2VT0
50 GF Score
Price €3.94
GF Value €3.01
! 4 Warning Signs
View Full Analysis

What is Lipocine Cyclically Adjusted FCF per Share?

Lipocine STU:2VT0 50 Cyclically Adjusted FCF per Share is €-3.52 as of Mar. 2026. GuruFocus rates STU:2VT0 with a GF Score™ of 50/100 and a GF Value™ of €3.01. The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Lipocine's adjusted free cash flow per share for the three months ended in Mar. 2026 was €-0.287. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-3.52 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 15.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Lipocine was 15.50% per year. The lowest was 15.50% per year. And the median was 15.50% per year.

As of today (2026-07-09), Lipocine's current stock price is €3.944. Lipocine's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was €-3.52. Lipocine's Cyclically Adjusted Price-to-FCF of today is .

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Lipocine was 0.26. The lowest was 0.05. And the median was 0.12.


Lipocine  (STU:2VT0) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Lipocine was 0.26. The lowest was 0.05. And the median was 0.12.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Lipocine Cyclically Adjusted FCF per Share Related Terms


Lipocine Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Lipocine's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lipocine Cyclically Adjusted FCF per Share Chart

Lipocine Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 108.57 -11.86 -17.30 -7.71 -3.83

Lipocine Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -11.36 -10.90 -11.26 -3.83 -3.52

STU:2VT0 vs NCEL, PTN, ALLR: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Lipocine's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lipocine Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lipocine's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Lipocine's Cyclically Adjusted Price-to-FCF falls into.


STU:2VT0
50GF Score
Lipocine Inc STU:2VT0
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lipocine Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Lipocine's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.287/330.2130*330.2130
=-0.287

Current CPI (Mar. 2026) = 330.2130.

Lipocine Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -4.306 241.018 -5.900
201609 -3.360 241.428 -4.596
201612 -2.247 241.432 -3.073
201703 -2.666 243.801 -3.611
201706 -3.670 244.955 -4.947
201709 -3.117 246.819 -4.170
201712 -2.909 246.524 -3.897
201803 -2.428 249.554 -3.213
201806 -1.875 251.989 -2.457
201809 -2.302 252.439 -3.011
201812 -1.544 251.233 -2.029
201903 -1.933 254.202 -2.511
201906 -1.565 256.143 -2.018
201909 -1.734 256.759 -2.230
201912 -1.652 256.974 -2.123
202003 -1.256 258.115 -1.607
202006 -1.237 257.797 -1.584
202009 -0.927 260.280 -1.176
202012 -0.772 260.474 -0.979
202103 -0.708 264.877 -0.883
202106 -0.375 271.696 -0.456
202109 -1.134 274.310 -1.365
202112 1.522 278.802 1.803
202203 -0.684 287.504 -0.786
202206 -0.549 296.311 -0.612
202209 -0.615 296.808 -0.684
202212 -0.349 296.797 -0.388
202303 -0.702 301.836 -0.768
202306 -0.584 305.109 -0.632
202309 -0.461 307.789 -0.495
202312 -0.349 306.746 -0.376
202403 0.413 312.332 0.437
202406 -0.434 314.175 -0.456
202409 -0.477 315.301 -0.500
202412 0.286 315.605 0.299
202503 -0.340 319.799 -0.351
202506 -0.305 322.561 -0.312
202509 -0.470 324.800 -0.478
202512 -0.371 324.054 -0.378
202603 -0.287 330.213 -0.287

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €-3.52 mean?
Lipocine (STU:2VT0) has a Cyclically Adjusted FCF per Share of €-3.52 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Lipocine and its competitors.
Is Lipocine's Cyclically Adjusted FCF per Share too high?
Lipocine's current Cyclically Adjusted FCF per Share is €-3.52. Overall, Lipocine has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.
How does Lipocine's Cyclically Adjusted FCF per Share compare to NCEL and PTN?
Lipocine's Cyclically Adjusted FCF per Share of €-3.52 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Lipocine and its competitors. Lipocine's current Cyclically Adjusted FCF per Share is €-3.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lipocine stock overvalued right now?
Lipocine (STU:2VT0) has a current Cyclically Adjusted FCF per Share of €-3.52. The stock's GF Value™ is €3.01, compared to a current price of €3.94 — trading 31% above its estimated fair value. The current Cyclically Adjusted FCF per Share is €-3.52. Lipocine's overall GF Score™ is 50/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Lipocine (STU:2VT0), the current Cyclically Adjusted FCF per Share is €-3.52 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lipocine (STU:2VT0) Overvalued in 2026?

Based on GuruFocus' analysis, Lipocine stock appears to be overvalued. The current stock price of €3.94 is trading 31% above its estimated GF Value™ of €3.01.

Key valuation signals for STU:2VT0:

  • Cyclically Adjusted FCF per Share: €-3.52
  • GF Value™: €3.01 vs. price of €3.94 (31% above fair value)
  • GF Score™: 50/100 with 4 warning signs

No single metric tells the full story. See the STU:2VT0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Lipocine Business Description

Other Exchanges LPCN:USA
Address 675 Arapeen Drive, Suite 202, Salt Lake City, UT, USA, 84108
Lipocine Inc is a clinical-stage biopharmaceutical company that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates, or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy (TRT). It also has other products in the pipeline, such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.
50GF Score

Get the complete analysis for STU:2VT0

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.94
Price
€3.01
GF Value